Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 2, 2004, Pages 2-6

  Berinstein, Neil L ^a   Mangel, Joy ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL MOTILITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MANTLE CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 1542408994     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.002     Document Type: Conference Paper

References (18)

1. International Lymphoma Study Group: The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
2. Hiddemann W, Brittinger G, Tiemann M, et al: Clinical characteristics and response to chemotherapy of mantle cell lymphomas-Results of a European survey. Blood 88:674a, 1996 (abstr)
3. Freedman AS, Neuberg D, Gribben JG, et al: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol 16:13-18, 1998
4. Barista I, Romaguera JE, Cabanillas F: Mantle cell lymphoma. Lancet Oncol 2:141-148, 2001
5. Haas R, Brittinger G, Meusers P, et al: Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 10:1975-1979, 1996
6. Blay JY, Sebban C, Surbiguet C, et al: High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: A single center experience on 18 patients. Bone Marrow Transplant 21:51-54, 1998
7. Khouri IF, Romaguera J, Kantarjian H, et al: H-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998
8. Vose JM, Bierman PJ, Weisenburger DD: Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 6:640-645, 2000
9. Andersen NS, Donovan JW, Borus JS, et al: Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 90:4212-4221, 1997
10. Plosker GL, Figgitt DP: Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 63:803-843, 2003
11. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
12. Johnson P, Glennie M: The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30:3-8, 2003 (suppl)
13. Romaguera J, Cabanillas F, Dang N, et al: Mantle cell lymphoma (MCL)-Update on results after R-HCVAD without stem cell transplant (SCT). Ann Oncol 13:8, 2002 (abstr)
14. Hiddemann W, Unterhalt M, Dreyling M, et al: The addition of rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood 100:92a, 2002 (abstr)
15. Dreyling MH, Forstpointner R, Repp R, et al: Combined immunochemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma-Final results of a prospective randomized trial of the GLSG. Hematol J 4:150, 2002 (abstr)
16. Gisselbrecht C, Mounier N: Rituximab: Enhancing outcomes of ASCT in NHL. Semin Oncol 30:28-33, 2003
17. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755, 2003
18. Mangel J, Leitch HA, Connors JM, et al: Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: A matched pair analysis. Ann Oncol 15:283-290, 2004